Idaho-based Kochava sues the FTC, claiming the agency is threatening to sue it for marketing geolocation data that might be used to track abortion clinic visits
FTC wrongly contends data could track visits to sensitive places such as clinics offering abortion, company claims
Context & Ripple Effects
Kochava's preemptive lawsuit lands in a market already rattled by post-Roe data demand: days earlier, Tapestri reported two companies seeking device data on abortion clinic visitors. Rather than wait for an FTC complaint, the Idaho broker is suing first, claiming the agency threatened action over geolocation data it says might reveal clinic visits.
The gambit set up a multi-year arc: the FTC filed suit anyway two weeks later ([[a:1157763|charging Kochava with selling data exposing visits to clinics, places of worship, and shelters]]), an Idaho federal judge later dismissed it for inadequate evidence of consumer harm, and the dispute ultimately ended in a settlement barring Kochava and subsidiary CDS from selling Americans' location data.
First-order effects
- Kochava shifts from defendant-in-waiting to litigant, forcing the FTC to justify its harm claims in court before any enforcement proceeds against the company's core data-sales business.
- The FTC's threat strategy is exposed publicly: by suing first, Kochava surfaces the agency's legal reasoning about sensitive-location tracking before a complaint could be framed on the agency's terms.
Second-order effects
- Rival brokers like Tapestri, already fielding buyer interest in clinic-visit data, face the same enforcement template — a court-tested precedent either legitimizes or constrains their own sales.
- Downstream buyers of geofenced location data come under scrutiny too, as the related coverage of [[a:840187|Veritas Society using geofenced data to target abortion clinic visitors with anti-abortion ads on Facebook, Instagram, and Snapchat]] shows how broker data converts into ad-platform campaigns.
Third-order effects
- The eventual settlement banning Kochava and CDS from selling Americans' location data suggests the dismissal was a delay, not a defeat — agencies can lose the evidentiary battle in court yet return through negotiated bans, raising the cost of staying in the sensitive-location data trade.
- If the pattern holds, data brokers face a structural split: location products tied to health, worship, or shelter visits become unsellable in the US market, pushing the industry toward consent-based architectures and away from raw behavioral resale.
The trend: US regulators are moving from evidentiary skirmishes to outright bans on selling location data that reveals visits to sensitive locations, with courts shaping the pace but not the direction.